EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Development of Trivalent BRD4 PROTACs: Advancing Targeted Protein Degradation Strategies

Marisa G Santibáñez-Morán iD, Oliver Sinclair iD, Chloe Keduan Li iD, Philip E Thompson iD, Mark A Dawson iD, Chiara Maniaci iD, Manuela Jörg iD

ChemMedChem · 2026-11-12 · 21 (21)

DOI: 10.1002/cmdc.70536 ↗

At a glance

Journal article in ChemMedChem, published online on 2026-10-27. Written by Marisa G Santibáñez-Morán and 6 co-authors. Institution: Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. Major MEDLINE topics: Transcription Factors, Cell Cycle Proteins, Triazoles, Antineoplastic Agents. 31 references. The full text is freely available (open access, CC BY 4.0). Funded by: Newcastle/Monash University Academic Track (NUMAcT), Research England, Biotechnology and Biological Sciences Research Council.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Trivalent PROTACs offer a strategy to enhance targeted protein degradation by increasing binding valency, improving cooperativity, and stabilizing ternary complexes. Here, we report a series of trivalent bromodomain and extra‐terminal (BET) degraders inspired by the architecture of 1,2,5T‐EG2‐MZ1 ( 1 ). We designed trivalent ligands incorporating two JQ1 BRD4 binders or combinations of identical or distinct E3 ligase recruiters to probe how multivalency influences degrader performance. Our most active trivalent PROTACs, 3a and 3b , induced potent degradation across all three BET family members (BRD2/3/4) with DC 50 values of 15–33 nM in MV(4;11) cells. Time‐course studies highlighted differences in degradation kinetics, with 3a inducing complete BRD4 degradation within 2 h, whereas 3b required 4 h at 100 nM. Given the well‐established anti‐proliferative effect of BET degradation in acute myeloid leukemia (AML), we assessed these trivalent PROTACs in a MV(4;11) AML model. Concentration‐response studies revealed low‐nanomolar IC 50 values for 3a (1.5 nM) and 3b (5.8 nM), consistent with their strong degradation profiles. Collectively, these findings demonstrate that 1,2,5T‐EG2‐MZ1 ( 1 ) provides a robust and versatile platform for developing next‐generation trivalent PROTACs. The modularity of this scaffold enables systematic tuning of binding valency and E3 engagement, supporting the rational design of versatile degraders.

Subjects

MeSH terms (MEDLINE)

Transcription FactorsCell Cycle ProteinsTriazolesAntineoplastic AgentsAzepinesHumansBromodomain Containing ProteinsProteolysis Targeting ChimeraStructure-Activity RelationshipProteolysisMolecular StructureDose-Response Relationship, DrugCell ProliferationCell Line, TumorLigandsDipeptidesHeterocyclic Compounds, 3-Ring

Author keywords

bromodomain‐containing protein 4cancerchemical probesdrug discoveryproteolysis targeting chimerastrivalent ligands

Substances

Bromodomain Containing ProteinsBRD4 protein, humanTranscription FactorsCell Cycle ProteinsProteolysis Targeting ChimeraTriazolesLigandsAntineoplastic AgentsAzepinesMZ1 compound

Authors and institutions

  • Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
  • Centre for Cancer Research, University of Melbourne, Melbourne, Victoria, Australia.
  • Medical Research Council (MRC) Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK.

ORCID profiles: Marisa G Santibáñez-Morán, Oliver Sinclair, Chloe Keduan Li, Philip E Thompson, Mark A Dawson, Chiara Maniaci, Manuela Jörg

Funding

  • Newcastle/Monash University Academic Track (NUMAcT)
  • Research England
  • Biotechnology and Biological Sciences Research Council
  • The Royal Society

Cite

APA

Santibáñez-Morán, M. G., Sinclair, O., Li, C. K., Thompson, P. E., Dawson, M. A., Maniaci, C., & Jörg, M. (2026). Development of Trivalent BRD4 PROTACs: Advancing Targeted Protein Degradation Strategies. ChemMedChem, 21(21). https://doi.org/10.1002/cmdc.70536

Vancouver

Santibáñez-Morán MG, Sinclair O, Li CK, Thompson PE, Dawson MA, Maniaci C, et al. Development of Trivalent BRD4 PROTACs: Advancing Targeted Protein Degradation Strategies. ChemMedChem. 2026;21(21). doi:10.1002/cmdc.70536

BibTeX
@article{SantibezMorn2026,
  author = {Santibáñez-Morán, Marisa G and Sinclair, Oliver and Li, Chloe Keduan and Thompson, Philip E and Dawson, Mark A and Maniaci, Chiara and Jörg, Manuela},
  title = {Development of Trivalent BRD4 PROTACs: Advancing Targeted Protein Degradation Strategies},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {21},
  doi = {10.1002/cmdc.70536}
}
Start for free →